Background. Knowledge of causes of sepsis in sub-Saharan Africa is limited. A better understanding of the microbiology of bloodstream infections could improve outcomes.
≥18 years with sepsis enrolled in a fluid resuscitation study from the medical casualty units of Mulago National Referral Hospital and Masaka Regional Referral Hospital in Uganda from May 2008 to May 2009 [17] . Written informed consent was obtained from each patient or a surrogate if the patient could not provide consent. At the time of enrollment, we obtained baseline demographic and clinical data including antibiotics received. We collected blood from 8 healthy Ugandan volunteers as negative controls. All whole blood samples were cryopreserved at −80° C until they were tested in 2015-2016.
Target Detection Using qPCR TAC
We incorporated primers and probes for 43 targets and 2 extrinsic controls on the TAC as previously described (Supplementary  Tables 1 and 2 ) [16] . Any quantification cycle (Cq) result of <40 was considered positive. Lower Cq values indicate higher quantity of target material present in the sample.
Cryptococcal Antigen Testing
We tested a convenience sample of available plasma specimens from 265 participants for the presence of cryptococcal antigen using lateral flow assay kits (Immuno-Mycologics Inc., Norman, OK, USA) following the manufacturer's instructions.
Statistical Analysis
We determined sensitivity and specificity for qPCR TAC results compared to standard culture results. We summarized participant characteristics as percentage for categorical variables and median with interquartile range (IQR) for continuous variables. We compared proportions with the χ 2 test and compared continuous variables with the Mann-Whitney U test. We evaluated relationships between qPCR TAC results and in-hospital mortality with logistic regression and adjusted for age, sex, and HIV infection. P values were 2-tailed, and <.05 was considered significant (SPSS, Version 22.0; IBM Corp, Armonk, New York).
RESULTS

Demographics and qPCR TAC Results
Of the 336 participants, the median (IQR) age was 34 (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) years, 175 (52%) were female, 282 (84%) were HIV-infected, and 90 (27%) died in-hospital (Table 1) . The clinical and laboratory data from the convenience sample were similar to those from the total enrolled cohort (Supplementary Table 3 ) [17] . All 336 samples yielded valid qPCR TAC results as described in Supplementary Table 2 . We tested positive samples again for the relevant targets with PCR assays that generated longer amplicons [16] . As seen previously, ~80% (277 of 346) of the TAC results were sequence-confirmed, and those that were able to be confirmed by long amplicon sequencing had significantly lower Cq values than those that were not (31.1 ± 4.7 vs 36.6 ± 1.7, p <.01) [16] .
No target was detected in any of the 8 Ugandan healthy volunteer controls. We detected at least one target in 245 of 336 participants (72%, Table 2 ). The most frequently detected targets were cytomegalovirus (CMV, n = 139, 41%), TB (n = 70, 21%), Plasmodium species (n = 35, 10%), and Streptococcus pneumoniae (n = 31, 9%). Excluding CMV, 138 (41%) participants had 1 target, 18 (5%) had 2 targets, and 1 (0.3%) had 3 targets identified by qPCR. Of the 139 cases of CMV viremia, there were 66 (40%) cases of bacterial coinfection including 28 (42%) that were identified by both qPCR and culture, 25 (38%) that were identified by qPCR only, and 13 (20%) that were identified by culture only. Compared to previously performed blood cultures, qPCR TAC performance varied by target averaging 61% sensitivity and 98% specificity (Table 3) . Overall, culture-positive samples had lower Cqs (31.4 ± 3.1, n = 65) than those that were culture-negative (33.1 ± 3.0, n = 61, p < .01).
qPCR TAC Results and In-hospital Mortality
CMV viremia was associated with in-hospital mortality, with 57 of 138 (41%) CMV-positive participants dying in hospital compared to 33 of 195 (17%) CMV-negative participants (odds ratio [OR] 3.5, 95% confidence interval [CI] 2.1-5.7, p < .01). We did not have any pathology data to determine end-organ involvement by CMV versus reactivation viremia in the setting of critical illness. There were 40 (12%) TB qPCR-positive/ culture-positive cases, 30 (9%) TB qPCR-positive/culture-negative cases, 29 (9%) TB qPCR-negative/culture-positive cases, and 237 (71%) TB qPCR-negative/culture-negative cases. The in-hospital mortality for these groups was 55%, 43%, 31%, and 20%, respectively (Table 4) . In multivariable analysis, CMV viremia (adjusted odds ratio [aOR] 3.19, 95% CI 1.83-5.54, p < .01) and a positive TB qPCR result with either a concurrent negative (aOR 2.85, 95% CI 1.18-6.88, p = .02) or positive (aOR 4.60, 95% CI 2.12-9.98, p < .01) TB culture result were independently associated with in-hospital mortality ( Table 4) .
The in-hospital mortality for S. pneumoniae qPCR-positive cases (n = 31) was 33% compared to 13% in-hospital mortality for qPCR-negative/culture-negative cases (aOR 2.18, 95% CI 0.89-5.30, p = .09). Plasmodium qPCR-positive cases had lower mortality (6%); however, there was not a statistically significant difference in mortality when compared to qPCR-negative/culture-negative cases (aOR 0.25, 95% CI 0.06-1.16, p = .08). Of the 2 Plasmodium infected participants that died, one had CMV viremia, and the other had S. pneumoniae coinfection. Seventeen of 265 participants (86% HIV-infected) had positive cryptococcal antigen (CrAg) assays; 6 were also Cryptococcus qPCR-positive, and 5 were Cryptococcus blood culture-positive. All positive CrAg results occurred in HIV-infected participants. In-hospital mortality for these participants was 59% (CrAg), 83% (Cryptococcus TAC), and 60% (Cryptococcus blood culture). The sensitivity of qPCR for identifying Cryptococcus versus culture was 80%. The sensitivity of qPCR for identifying CrAg assay positive cases was 29% and specificity was 100%. The qPCR sensitivity improved to 55% (6 of 11) for cases with CrAg assay titer ≥1:2560. Four of 5 cases with low CrAg assay titers (<1:80) had a second causative pathogen identified in blood culture.
Table 2. Quantitative Polymerase Chain Reaction TaqMan Array Card Detection in Blood From 336 Adult Patients Admitted to Hospital With Sepsis in Uganda
Pathogen, n (%) Total (n = 336) HIV-infected a (n = 282) HIV-negative (n = 50) CMV 139 (41) 129 (46) 8 (16) Mycobacterium tuberculosis 70 (21) 63 (22) 6 (12) Plasmodium species 35 (10) 18 (6) 17 (34) Streptococcus pneumoniae 31 (9) 27 (10) 4 (8) Dengue 17 (5) 16 (6) 1 (2) Escherichia coli 16 (5) 11 (4) 5 (10) Cryptococcus neoformans
Staphylococcus aureus 4 (1) 3 (1) 1 (2) Toxoplasma gondii 4 (1) 3 (1) 1 (2) Acinetobacter baumannii Average PCR cycle of quantification (Cq) and standard deviation are shown in parentheses.
Abbreviation: qPCR, quantitative polymerase chain reaction.
Quantity of Amplified DNA and In-hospital Mortality
The quantities of TB, CMV, and S. pneumoniae DNA as measured by qPCR (Cq) appeared to directly correlate with mortality ( Figure 1 ). In multivariable analysis that included continuous Cq values for CMV and TB, we found an aOR of in-hospital mortality of 1.4 (95% CI 1.2-1.7, p < .01) and 1.6 (95% CI 1.2-1.9, p < .01) for each 10-fold increase in quantity for CMV and TB, respectively.
Antimicrobial Therapy and In-hospital Mortality
There were 43 different combinations of antibacterial therapy administered to 324 of 336 (96%) participants in our study. Mortality from TB infection remained high despite anti-TB therapy. There were 13 (13.1%) of 99 confirmed TB cases (by culture, qPCR, or both) who received empirical anti-TB therapy, Figure 1 . Association of CMV, Mycobacterium tuberculosis, Plasmodium, Streptococcus pneumoniae, and DNA quantity as determined by quantification cycle with mortality for 336 adult patients admitted to hospital with sepsis in Uganda. The x-axis shows the Cq ranges, whereas the y-axis shows the in-hospital mortality associated with each pathogen according to the corresponding Cq cutoff. The dark bar indicates the mortality rate for TAC negative patients for all the pathogens interrogated. Abbreviations: CMV, cytomegalovirus; Cq, quantification cycle; TAC, TaqMan Array Card. 
DISCUSSION
In this work, we demonstrate the utility of a multi-target qPCR TAC in the evaluation of sepsis in sub-Saharan Africa. We found CMV and TB were the most commonly identified TAC targets in the blood of patients with sepsis in Uganda and were independently associated with increased in-hospital mortality. Future use of qPCR TAC to screen blood for multiple targets may be useful for therapeutic triage of individual patients, outbreak investigations, and determination of local epidemiology through use in sentinel laboratories.
There are abundant data that indicate that the time to appropriate therapy for bloodstream infections correlates with improved mortality [18] [19] [20] . However, given the large number of potential pathogens, there is a need for improved syndromic diagnostic methods. Blood culture, considered the gold standard for microbiological diagnosis, is expensive, requires several days to yield a result, and is affected by antibiotic pre-exposure which is common in many settings. Serologic tests are often unavailable. PCR tests are faster and can be designed for virtually any pathogen. Previous studies using commercial PCRbased methods to detect pathogens directly in blood including SeptiFast®, SepsiTest™ and IRIDICA BAC BSI Assay used ≥2mL of blood and revealed only a 48-84% sensitivity compared with blood culture [21] . This low to moderate sensitivity range presumably reflects low numbers of pathogens in blood, as has been clearly demonstrated for Salmonella enterica typhi [22] .
Other challenges to PCR in blood are the typically low sample volumes and inhibitory substances within blood. In this context, we were not surprised to observe a 61% overall sensitivity of qPCR TAC versus culture, particularly given the sub-microliter volumes of nucleic acid required for qPCR TAC. We were limited to less than 2mL of whole blood per sample in this study, and we would advocate using larger volumes to improve sensitivity. Another factor was that these blood samples were stored ~7 years prior to testing; thus, specimen degradation could have occurred. However, it has been shown that DNA in blood samples frozen at −80 o C for 16 months was preserved well [23] .
A systematic review of commercial PCR methods used to identify bacteria and fungi in blood found 81-86% specificity versus blood culture, in other words a 14-19% "false positive" rate [21] . An important finding of ours is that the qPCR-positive/ culture-negative specimens were not false information but were clinically significant. Specifically, a TB qPCR-positive case, even if culture-negative, exhibited a high mortality. In fact, the TB qPCR-positive/culture-negative mortality was higher than and maintained statistically significant prognostic information over the TB qPCR-negative/culture-positive mortality. This finding combined with the inverse relationship between Cq values and mortality suggests a higher burden of infection for TB qPCR-positive/culture-negative cases compared to TB qPCR-negative/culture-positive cases. Therefore we feel qPCR-positive/culture-negative results in blood should be reexamined and not reflexively dismissed.
As for the TB qPCR TAC performance itself versus culture, our results are similar to most other studies. A study found a sensitivity of 42% and specificity of 100% for PCR compared to a gold standard of TB culture positivity from any clinical specimen [24] . A small study from Malawi reported a 56% concordance between Xpert MTB/RIF PCR detection from blood and blood culture in HIV-infected patients with a high clinical suspicion for TB [25] . In a study from Uganda, PCR identified TB in blood with a sensitivity and specificity of 33% and 97% respectively when using 2 mL samples and 71% and 96% respectively when using 10 mL samples [26] .
The 50% TB mortality we observed was also expected. This finding is similar to studies from Malawi, South Africa, Tanzania, and Uganda, which found an associated mortality of 21-50% [7, [27] [28] [29] . In our study, few patients received anti-TB therapy. A trend towards lower mortality was observed in TB patients who received anti-TB therapy versus those who did not, although mortality remained high and the difference was not statistically significant. In 317 HIV-infected sputum smear-negative patients presenting with clinical danger signs in Uganda, mortality was 20% if patients received empiric anti-TB therapy compared to 36% mortality if they did not [30] . In another study of 34 patients in Uganda with confirmed mycobacteremia, the proportion of patients who died at one year was significantly lower in those who were receiving anti-TB therapy (23%) at the time of culture positivity compared with those who were not receiving anti-TB therapy (58%) [28] . These results suggest that early identification and treatment of mycobacteremia can improve outcomes, and TB should be raised on the differential diagnosis of inpatients with sepsis in TB endemic settings.
CMV was the most frequent qPCR TAC target found in this patient population, and CMV viremia was independently associated with mortality. In critically ill patients, CMV reactivation is known to be associated with increased mortality; however, CMV viremia does not usually require treatment [31] [32] [33] [34] . A randomized clinical trial of ganciclovir for critically ill CMVseropositive adults showed no difference in mortality between treatment groups [34] . CMV seroprevalence is approximately 80% in sub-Saharan Africa, and CMV viremia in dried blood spots was independently associated with increased risk of death in HIV-infected patients from Tanzania [35] [36] [37] . Although we did not have clinical data regarding end-organ damage due to CMV viremia, given the high number of bacterial coinfections in CMV viremia cases, we believe the CMV viremia was likely a prognostic marker but not causal for mortality. In support of the association between CMV reactivation and underlying disease severity is our finding that lower Cq values were associated with increased mortality in our multivariable analysis.
The 3 leading qPCR TAC targets we detected, CMV, TB and S. pneumoniae, all exhibited an inverse relationship between Cq and in-hospital mortality. Therefore, PCR positivity may reflect a higher burden of infection, which is associated with mortality. Overall, S. pneumoniae was associated with considerably lower mortality than TB perhaps because standard therapy for critically ill patients would be likely to treat this pathogen. However, S. pneumoniae showed a high mortality similar to TB at its highest bacterial load (i.e., lowest Cq), perhaps because of overwhelming infection. We presume the low mortality associated with Plasmodium positivity was because this may have represented incidental asymptomatic parasitemia [38] .
There were also some cases of Cryptococcus, Dengue virus, and Rickettsia species identified by qPCR TAC. Although Cryptococcus can be readily identified by the antigen test, cryptococcosis remains associated with high mortality rates [39] . Because 4 of 5 cases with low CrAg assay titers (<1:80) had a second causative pathogen identified in blood culture, it is unlikely that cryptococcosis was the etiology of sepsis in these cases. Dengue and Rickettsia are not easily recognized or considered as pathogens in critically ill patients in this region. However, spotted fever and typhus group rickettsiosis have been identified in febrile patients in Tanzania and Rickettsia species are commonly found in dog fleas in Uganda [12, 40] . Rickettsial infections are treatable with doxycycline, and a better understanding of which patients are likely to present with a rickettsial infection could help guide empiric therapy.
There were limitations to this study. Although the overall sample size of 336 was substantial, on a per pathogen basis we did not have sufficient power to conduct all analyses. Although we tested for 43 pathogens, there are still others that one might want to include. Not all qPCR TAC targets could be confirmed through standard testing due to specimen availability. With regard to CMV specifically, detection of CMV in whole blood is generally greater than that obtained in plasma, and plasma has been advocated as a better sample type for measuring CMV response to therapy; however, that was not our goal or of great relevance to this setting [41, 42] . Additionally, the qPCR TAC platform is well suited to high throughput testing but less well suited to clinical care because it requires a manual nucleic acid extraction method and tests 8 samples at once. Although molecular testing is expensive (~$50-100 reagent costs per sample), blood culture and other methodologies are also costly and imperfect.
In summary, in a predominantly HIV-infected population with sepsis, we confirmed that TB is the leading cause of bacteremia, which is associated with high mortality. CMV viremia was also independently associated with mortality. In total, we identified 19 different targets including many that would not be treated with standard empiric antibiotics (e.g. Rickettsia species) or require treatment (e.g., Dengue virus). We believe this work demonstrates the principle that a pan-molecular quantitative assay that screens for multiple targets in blood would be useful to provide therapeutic and prognostic information, particularly in settings with a high burden of HIV and other infectious diseases. For example, the qPCR TAC assay could identify the need for early TB therapy, CMV viremia as a marker for early mortality, and S. pneumoniae as an indicator of intermediate mortality (33%); or if nothing is positive with a large panel, this could portend a better prognosis. 
